



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Wenbin Hou,
✉ houwenbin@irm-cams.ac.cn
Shunchang Jiao,
✉ jiaoshunchang@cscsco.org.cn

SPECIALTY SECTION
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

RECEIVED 08 January 2023
ACCEPTED 25 January 2023
PUBLISHED 31 January 2023

CITATION
Liu M, Hu T, Gou W, Chang H, Li Y, Li Y,
Zuo D, Hou W and Jiao S (2023),
Corrigendum: Exploring the
pharmacological mechanisms of icaritin
against nasopharyngeal carcinoma *via*
network pharmacology and
experimental validation.
Front. Pharmacol. 14:1140018.
doi: 10.3389/fphar.2023.1140018

COPYRIGHT
© 2023 Liu, Hu, Gou, Chang, Li, Li, Zuo,
Hou and Jiao. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma *via* network pharmacology and experimental validation

Minglu Liu¹, Tong Hu^{2,3}, Wenfeng Gou², Huajie Chang², Yanli Li²,
Yiliang Li², Daiying Zuo³, Wenbin Hou^{2*} and Shunchang Jiao^{1*}

¹Department of Medical Oncology, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China, ²Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China, ³Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China

KEYWORDS

icaritin, nasopharyngeal carcinoma, ROS, senescence, network pharmacology

A Corrigendum on

Exploring the pharmacological mechanisms of icaritin against nasopharyngeal carcinoma *via* network pharmacology and experimental validation

by Liu M, Hu T, Gou W, Chang H, Li Y, Li Y, Zuo D, Hou W and Jiao S (2022) *Front. Pharmacol.* 13: 993022. doi: 10.3389/fphar.2022.993022

In the published article, there was an error in the **Author list**. The corrected author list appears below:

“Minglu Liu¹, Tong Hu^{2,3}, Wenfeng Gou², Huajie Chang², Yanli Li², Yiliang Li², Daiying Zuo³, Wenbin Hou^{2*}, Shunchang Jiao^{1,*}”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.